Evidence map›Paper›PMID 24084496›Full record

Trial reportOphthalmology2014

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

Juan E Grunwald, Ebenezer Daniel, Jiayan Huang, Gui-Shuang Ying, Maureen G Maguire, Cynthia A Toth, Glenn J Jaffe, Stuart L Fine, Barbara Blodi, Michael L Klein and 4 more

3 registry-linked trialsOpen access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 258 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
258citing papers in PubMed, 3 pooled it
51.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00593450 phase3completednot on this map

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)

TypeinterventionalSponsorUniversity of PennsylvaniaRan2008 to 2015Enrolled1,208ConditionsAge Related Macular DegenerationArmsranibizumab, bevacizumab
NCT03042871 phase4completednot on this mapstarted 2015, after this paper: background citation

Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study

TypeinterventionalSponsorZhongshan Ophthalmic Center, Sun Yat-sen UniversityRan2015 to 2018Enrolled54ConditionsChoroidal NeovascularizationArms0.5mg intravitreal ranibizumab
NCT04655482 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

Treat-and-extend Using Aflibercept for Type 3 Neovascularization

TypeinterventionalSponsorKim's Eye HospitalRan2021 to 2024Enrolled30ConditionsRetinal Angiomatous ProliferationArmsAflibercept Injection
3 · Its place in the literature

Who cites it

258 citing papers in PubMed, 3 syntheses or guidelines pooled it, 578 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. To investigate treat and extend versus pro re nata regimen in neovascular age-related macular degeneration: results from the IDEM study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Trial
  17. Choroidal vascularity across aging and the spectrum of age-related macular degeneration: an AI-based OCT study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  18. Article
  19. Article
  20. Article

198 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Juan E GrunwaldDepartment of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: juangrun@mail.med.upenn.edu.
Ebenezer DanielDepartment of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Jiayan HuangDepartment of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Gui-Shuang YingDepartment of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Maureen G MaguireDepartment of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Cynthia A TothDepartment of Ophthalmology, Duke University, Durham, North Carolina; Department of Biomedical Engineering, Duke University, Durham, North Carolina.
Glenn J JaffeDepartment of Ophthalmology, Duke University, Durham, North Carolina; Duke Reading Center, Duke University Eye Center, Durham, North Carolina.
Stuart L FineDepartment of Ophthalmology, University of Colorado-Denver, Aurora, Colorado.
Barbara BlodiDepartment of Ophthalmology, University of Wisconsin, Madison, Wisconsin.
Michael L KleinCasey Eye Institute, Oregon Health Sciences University, Portland, Oregon.
Alison A MartinCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Stephanie A HagstromCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Daniel F MartinCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
CATT Research Group
University of Pennsylvania · USCleveland Clinic · USDuke University · USOregon Health & Science University · USUniversity of Colorado Denver · USUniversity of Wisconsin–Madison · US

Funding

Coordinating Center for the Comparison of AMD Treatments TrialsU10EY017823 · NEI · UNIVERSITY OF PENNSYLVANIA · PI MAGUIRE, MAUREEN G · 2006 to 2012
$19.2M
Photograph Reading Center for the Comparison of AMD Treatment TrialsU10EY017826 · NEI · UNIVERSITY OF PENNSYLVANIA · PI GRUNWALD, JUAN E · 2006 to 2013
$2.8M
Comparison of AMD Treatment Trials-OCT Reading CenterU10EY017825 · NEI · DUKE UNIVERSITY · PI JAFFE, GLENN · 2006 to 2013
$2.3M
Chair Grant for the Comparison of AMD Treatment TrialsU10EY017828 · NEI · EMORY UNIVERSITY · PI MARTIN, DANIEL F · 2006 to 2012
$1.9M
NEI NIH HHS U10 EY017823NEI NIH HHS U10 EY017825NEI NIH HHS U10 EY017826NEI NIH HHS U10 EY017828
6 · The paper itself

Abstract

purposeTo describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

designCohort within a randomized clinical trial.

participantsWe analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.

methodsEyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs).

main outcome measuresDevelopment of GA.

resultsBy 2 years, GA developed in 187 of 1024 patients (18.3%). Baseline risk factors for GA development included baseline visual acuity (VA) ≤20/200 (aHR, 2.65; 95% confidence interval [CI], 1.43-4.93), retinal angiomatous proliferation (RAP; aHR, 1.69; 95% CI, 1.16-2.47), GA in the fellow eye (aHR, 2.07; 95% CI, 1.40-3.08), and intraretinal fluid at the foveal center (aHR, 2.10; 95% CI, 1.34-3.31). Baseline factors associated with lower risk for GA development included blocked fluorescence (aHR, 0.49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 μ (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared with ≤75 μ (aHR, 0.31; 95% CI, 0.19-0.50), and vitreomacular attachment (aHR, 0.55; 95% CI, 0.31-0.97). Ranibizumab compared with bevacizumab had a higher risk (aHR, 1.43; 95% CI, 1.06-1.93), and monthly dosing had a higher risk (aHR, 1.59; 95% CI, 1.17-2.16) than PRN dosing. There were no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.

conclusionsApproximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabCohort StudiesFemaleFluorescein AngiographyFollow-Up StudiesGenotyping TechniquesGeographic AtrophyHumansIncidenceMaleMiddle AgedProportional Hazards ModelsAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabRanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID24084496
PMCPMC3892560
OpenAlexW2131192872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.